When is it appropriate to use Evenity (romosozumab) in adults with osteoporosis, such as post‑menopausal women or men over 50 with a recent major osteoporotic fracture or who have failed bisphosphonate therapy?

When to Use Evenity (Romosozumab) for Osteoporosis

Evenity should be used in postmenopausal women with osteoporosis at very high fracture risk—specifically those with a history of osteoporotic fracture, multiple fracture risk factors, or who have failed or are intolerant to other osteoporosis therapies—but must NOT be initiated in patients with recent myocardial infarction or stroke within the past year. 1

Primary Indications

Approved Patient Population

Evenity is FDA-approved exclusively for postmenopausal women at high fracture risk 1. The drug is not currently approved for men, despite being studied in this population 2.

Specific Clinical Scenarios for Use

Very High-Risk Patients:

• Recent major osteoporotic fracture (especially vertebral fractures)
• Multiple or severe vertebral fractures
• Failed bisphosphonate therapy after at least 3 years of treatment (mean 6.2 years in trials) 2
• Failed or intolerant to teriparatide or abaloparatide 2
• Prior radiation exposure (where other anabolics may be contraindicated) 2

The 2020 AACE/ACE guidelines explicitly position romosozumab as a "rescue drug" for patients at very high fracture risk 2.

Critical Cardiovascular Contraindications

Absolute Contraindication:

• Myocardial infarction or stroke within the preceding year 1

Relative Contraindication (requires careful risk-benefit assessment):

• High cardiovascular risk factors
• History of cardiovascular disease beyond 1 year

This black-box warning stems from Phase III trial data showing significantly more serious cardiovascular events with romosozumab compared to alendronate, though the increased risk was small and did not persist 2. The cardiovascular signal was not observed in the placebo-controlled trial 2.

Treatment Duration and Sequential Therapy

Duration: Limit to 12 monthly doses only 1

• The anabolic effect wanes after 12 months 1

Mandatory Sequential Therapy: You must follow romosozumab with an antiresorptive agent (bisphosphonate or denosumab) to prevent bone loss and maintain fracture reduction 3, 2. There is no rationale for a washout period—transition immediately 2.

Recent real-world data shows both denosumab and bisphosphonates are effective as sequential therapy, with denosumab showing superior sustained BMD gains in the second year 4. Patients without sequential therapy experienced significant BMD decline (-5.4% lumbar spine) 4.

Efficacy Data Supporting Use

Romosozumab demonstrated in Phase III trials 2:

• 73% reduction in vertebral fractures vs. placebo at 12 months
• 34% reduction vs. alendronate at 12 months
• 27-33% reduction in clinical fractures at 12 and 24 months
• 38% hip fracture reduction (vs. alendronate at 24 months)
• Superior BMD gains vs. teriparatide: lumbar spine (9.8% vs. 5.4%), femoral neck (3.2% vs. -0.2%), total hip (2.9% vs. -0.5%) in bisphosphonate-pretreated patients 2

Practical Considerations

Prior Bisphosphonate Exposure: Romosozumab remains effective even after prolonged bisphosphonate therapy (≥3 years), showing greater BMD gains than teriparatide in this population 2. Real-world data confirms significant BMD increases regardless of prior bisphosphonate exposure 5, 6.

Monitoring:

• Supplement with calcium and vitamin D during treatment 1
• Expect P1NP increases of ~450% and CTX increases of ~30% 6
• Approximately 60% of patients achieve the BMD surrogate threshold effect for minimal fracture risk at 12 months 5

Common Pitfalls to Avoid

1. Do not use in men—not FDA approved despite trial data 2
2. Do not extend beyond 12 months—efficacy wanes 1
3. Do not skip sequential therapy—BMD losses occur rapidly without it 3, 4
4. Do not use in recent MI/stroke patients (within 1 year) 1
5. Do not use as first-line therapy—reserve for very high-risk patients who have failed or cannot tolerate other options 2